Failed early
Laquinimod: protect nerve tissue in primary progressive MS
primary progressive MS · T-cell co-stimulation / cytokine targeting
Controlled phase 2 trials were negative.
Laquinimod was refused in the EU. A positive trial result does not mean the medicine is available.
- Trials
- 1
- Running now
- 0
- Controlled phase 2/3 trials
- 1
- People in controlled trials
- 374
Deciding trials (phase 2): 0 met, 1 did not.
Other linked trials: 0
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
Phase 2 · 2015 · Placebo-controlled · MSFT-NCT02284568
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-27First listed as Failed early
Related hypotheses
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error